drugset
drugset / Trial / NCT07368270

Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT07368270 ↗

Phase 1 Recruiting 30 enrolled Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and tolerability of anti-PD1 armored CD19 CAR-T Cells in adult subjects with relapsed or refractory diffuse large B-cell lymphoma.

Timeline

Start
2026-01
Primary completion
2027-01
Completion
2029-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Anti-PD1 armored CD19 CAR-T cells Cell therapy 1e+06 cells/kg Intravenous
Subject Anti-PD1 armored CD19 CAR-T cells Cell therapy 3e+06 cells/kg Intravenous
Subject Anti-PD1 armored CD19 CAR-T cells Cell therapy 9e+06 cells/kg Intravenous
Subject Anti-PD1 armored CD19 CAR-T cells Cell therapy 6e+08 cells Intravenous

Indications

diffuse large B-cell lymphoma